ReviewTrends in pharmacological sciences2010
Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies.
Review in Trends in pharmacological sciences, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 329 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
329 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- Exploiting blood-based biomarkers to align preclinical models with human traumatic brain injury.Brain : a journal of neurology · 2025Pooled it
- Preclinical Studies on Mechanisms Underlying the Protective Effects of Propranolol in Traumatic Brain Injury: A Systematic Review.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2024Pooled it
- Characteristic of clinical trials related to traumatic brain injury registered on ClinicalTrials.gov over the past two decades (2004-2023).Frontiers in medicine · 2024Pooled it
- Can transcranial photobiomodulation improve cognitive function in TBI patients? A systematic review.Frontiers in psychology · 2024Pooled it
- A Systematic Review of ASL Perfusion MRI in Mild TBI.Neuropsychology review · 2023Pooled it
- Efficacy and safety of erythropoietin for traumatic brain injury.BMC neurology · 2020Pooled it
- Current Synthesis and Systematic Review of Main Effects of Calf Blood Deproteinized Medicine (ActoveginInternational journal of molecular sciences · 2020Pooled it
- Pre-Clinical Testing of Therapies for Traumatic Brain Injury.Journal of neurotrauma · 2018Guideline
- Magnetic Resonance Imaging Pilot Study of Intravenous Glyburide in Traumatic Brain Injury.Journal of neurotrauma · 2020Trial
- The Profile of MMP-9, MMP-9 mRNA Expression, -1562 C/T Polymorphism and Outcome in High-risk Traumatic Brain Injury: The Effect of Therapeutic Mild Hypothermia.Neurologia medico-chirurgica · 2017Trial
- In situ delivery of cannabidiol-loaded GelMA sponge attenuates cerebral edema and neuroinflammation in traumatic brain injury.Materials today. Bio · 2026Article
- AMPA Receptor Antagonists in Preclinical Models of Traumatic Brain Injury: A Systematic Review and Meta-analysis of Animal Studies.Neurocritical care · 2026Article
- MicroFace maps microglial morphology remodeling, revealing spatial zones and bifurcated trajectories during brain microinjury recovery.iScience · 2026Article
- Development of aBioactive materials · 2026Article
- Cell apoptosis in ischemic stroke: Focus on lipid metabolism.Neural regeneration research · 2026Article
- Mitochondrial Dysfunction in Traumatic Brain Injury and Its Theranostic Implications.Biomolecules · 2026Review
- Topiramate protects against neuroinflammation in response to traumatic brain injury via activating Sirt1 signaling.Scientific reports · 2026Article
- Role of insulin-like growth factor-1/2 and related signaling in parkinson's disease.Metabolic brain disease · 2026Review
- Multi-omics integration reveals TIM-4 as a master regulatory hub of neuroinflammation and neuronal cell death.Frontiers in cell and developmental biology · 2026Article
- Benzoate Drugs for Traumatic Brain Injury.Journal of clinical & experimental immunology · 2026Article
269 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Traumatic brain injury (TBI) causes secondary biochemical changes that contribute to subsequent tissue damage and associated neuronal cell death. Neuroprotective treatments that limit secondary tissue loss and/or improve behavioral outcome have been well established in multiple animal models of TBI. However, translation of such neuroprotective strategies to human injury have been disappointing, with the failure of more than thirty controlled clinical trials. Both conceptual issues and methodological differences between preclinical and clinical injury have undoubtedly contributed to these translational difficulties. More recently, changes in experimental approach, as well as altered clinical trial methodologies, have raised cautious optimism regarding the outcomes of future clinical trials. Here we critically review developing experimental neuroprotective strategies that show promise, and we propose criteria for improving the probability of successful clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.